{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:31:04Z","timestamp":1786714264299,"version":"build-2736575974"},"reference-count":42,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"unspecified","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"AstraZeneca, Ltd","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,8,5]]},"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Long-term survival of extensive-stage small-cell lung cancer (ES-SCLC) remains rare, with most patients experiencing disease progression during maintenance therapy. Poly (ADP-ribose) polymerase (PARP) inhibitors have the potential to confer antitumor activity, modify tumor immunogenicity, and sensitize tumors to anti-programmed cell death protein 1\/programmed death-ligand 1 therapy. We conducted this phase 2 trial to investigate the efficacy and safety of durvalumab plus olaparib as maintenance therapy in patients with ES-SCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This was a multicenter, single-arm, phase II trial that enrolled 60 patients with previously untreated ES-SCLC (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05245994\">NCT05245994<\/jats:ext-link>\n                      ). Patients received durvalumab (1,500 mg) combined with platinum-etoposide chemotherapy intravenously every 21 days for up to four cycles, followed by maintenance therapy with durvalumab (1,500 mg every 28 days) and oral olaparib (300 mg two times a day) until disease progression or unacceptable toxicity. Multi-omics analyses were performed to characterize molecular subtypes associated with clinical outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The combination regimen demonstrated promising efficacy, with an alive and progression-free at 12 months rate of 25.0%, an objective response rate of 73.3%, a median progression-free survival of 6.8 months, and a median overall survival of 14.6 months. Multi-omics profiling identified a hypomethylation subgroup (cluster 1) that was associated with significantly improved survival outcomes. Further analysis revealed that this subtype exhibited enhanced antigen presentation machinery, a favorable cytokine profile, and suppression of DNA damage repair (DDR) pathways, potentially through elevated promoter methylation and transcriptional silencing of specific DDR genes, which together were associated with the favorable outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study presents the first prospective evidence supporting durvalumab plus olaparib as maintenance therapy in ES-SCLC. Multi-omics analysis identifies that DNA hypomethylation status may enrich for patients who benefit from PARP inhibition and immunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05245994\">NCT05245994<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2026-015066","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T12:45:21Z","timestamp":1786711521000},"page":"e015066","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["DNA hypomethylation identifying clinical benefit subgroup of small-cell lung cancer: multi-omics analysis of a phase II trial with durvalumab plus olaparib as maintenance therapy"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct05245994","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05245994","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05245994","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7148-7608","authenticated-orcid":false,"given":"Yuanyuan","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiming","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Institute of Cancer Research, Henan Academy of Innovations in Medical Science, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2997-1855","authenticated-orcid":false,"given":"Bijing","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Jia","sequence":"additional","affiliation":[{"name":"Affiliated Dongguan Hospital of Southern Medical university, Dongguan People Hospital, Dongguan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9301-0130","authenticated-orcid":false,"given":"Xianling","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Xiangya Hospital of Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuxiang","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Institute of Cancer Research, Henan Academy of Innovations in Medical Science, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Zhujiang Hospital of Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4685-3055","authenticated-orcid":false,"given":"Ting","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunpeng","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfeng","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1789-5088","authenticated-orcid":false,"given":"Yan","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"2026081405451402000_14.8.e015066.1","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1158\/1078-0432.CCR-23-1159","article-title":"Facts and Hopes on Cancer Immunotherapy for Small Cell Lung Cancer","volume":"30","author":"Zugazagoitia","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026081405451402000_14.8.e015066.2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.0560"},{"key":"2026081405451402000_14.8.e015066.3","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.87"},{"key":"2026081405451402000_14.8.e015066.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01881"},{"key":"2026081405451402000_14.8.e015066.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064"},{"key":"2026081405451402000_14.8.e015066.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32222-6"},{"key":"2026081405451402000_14.8.e015066.7","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jtho.2024.03.008","article-title":"Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial","volume":"19","author":"Cheng","year":"2024","journal-title":"J Thorac Oncol"},{"key":"2026081405451402000_14.8.e015066.8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1001\/jamaoncol.2024.5019","article-title":"Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical Trial","volume":"11","author":"Cheng","year":"2025","journal-title":"JAMA Oncol"},{"key":"2026081405451402000_14.8.e015066.9","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.01363"},{"key":"2026081405451402000_14.8.e015066.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01011-6"},{"key":"2026081405451402000_14.8.e015066.11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.7672"},{"key":"2026081405451402000_14.8.e015066.12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00264"},{"key":"2026081405451402000_14.8.e015066.13","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.semcancer.2022.07.008","article-title":"Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review","volume":"86","author":"Xiong","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"2026081405451402000_14.8.e015066.14","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0112"},{"key":"2026081405451402000_14.8.e015066.15","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1020"},{"key":"2026081405451402000_14.8.e015066.16","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-38534-6","article-title":"Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models","volume":"9","author":"Wang","year":"2019","journal-title":"Sci Rep"},{"key":"2026081405451402000_14.8.e015066.17","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2083755","article-title":"PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors","volume":"11","author":"Staniszewska","year":"2022","journal-title":"Oncoimmunology"},{"key":"2026081405451402000_14.8.e015066.18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30324-7"},{"key":"2026081405451402000_14.8.e015066.19","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaoncol.2019.1029","article-title":"Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer","volume":"5","author":"Vinayak","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026081405451402000_14.8.e015066.20","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/jamaoncol.2019.1048","article-title":"Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma","volume":"5","author":"Konstantinopoulos","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026081405451402000_14.8.e015066.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.04.026"},{"key":"2026081405451402000_14.8.e015066.22","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jtho.2024.10.021","article-title":"Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929","volume":"20","author":"Karim","year":"2025","journal-title":"J Thorac Oncol"},{"key":"2026081405451402000_14.8.e015066.23","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.71"},{"key":"2026081405451402000_14.8.e015066.24","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0133-9"},{"key":"2026081405451402000_14.8.e015066.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.12.014"},{"key":"2026081405451402000_14.8.e015066.26","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.semcancer.2020.11.006","article-title":"Epigenetic landscape of small cell lung cancer: small image of a giant recalcitrant disease","volume":"83","author":"Khan","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"2026081405451402000_14.8.e015066.27","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2015.38"},{"key":"2026081405451402000_14.8.e015066.28","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1038\/s43018-022-00415-9","article-title":"cfDNA methylome profiling for detection and subtyping of small cell lung cancers","volume":"3","author":"Chemi","year":"2022","journal-title":"Nat Cancer"},{"key":"2026081405451402000_14.8.e015066.29","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-025-02252-5","article-title":"Harnessing local and system immune profiling delineating differential responders to first-line sintilimab (anti-PD-1 antibody) combined with chemotherapy in extensive-stage small cell lung cancer: an exploratory biomarker analysis of a phase II study","volume":"10","author":"Xie","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"2026081405451402000_14.8.e015066.30","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s13258-022-01340-y","article-title":"Identification of DNA methylation and genetic alteration simultaneously from a single blood biopsy","volume":"45","author":"Chen","year":"2023","journal-title":"Genes Genomics"},{"key":"2026081405451402000_14.8.e015066.31","doi-asserted-by":"publisher","DOI":"10.1101\/gr.196394.115"},{"key":"2026081405451402000_14.8.e015066.32","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3152"},{"key":"2026081405451402000_14.8.e015066.33","doi-asserted-by":"publisher","DOI":"10.1101\/gr.211854.116"},{"key":"2026081405451402000_14.8.e015066.34","doi-asserted-by":"crossref","DOI":"10.1186\/s12014-022-09389-3","article-title":"Novel plasma protein biomarkers from critically ill sepsis patients","volume":"19","author":"Van Nynatten","year":"2022","journal-title":"Clin Proteomics"},{"key":"2026081405451402000_14.8.e015066.35","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26209964","article-title":"Checkpoint Blockade Efficacy in Uveal Melanoma Is Linked to Tumor Immunity, CD28, and CCL8","volume":"26","author":"Koch","year":"2025","journal-title":"Int J Mol Sci"},{"key":"2026081405451402000_14.8.e015066.36","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0066-7"},{"key":"2026081405451402000_14.8.e015066.37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00793"},{"key":"2026081405451402000_14.8.e015066.38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1128"},{"key":"2026081405451402000_14.8.e015066.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.05.008"},{"key":"2026081405451402000_14.8.e015066.40","doi-asserted-by":"crossref","first-page":"189502","DOI":"10.1016\/j.bbcan.2025.189502","article-title":"Role of CCL8 in cancer immunity and tumor progression: Implications for cancer treatment","volume":"1880","author":"Jeong","year":"2025","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"2026081405451402000_14.8.e015066.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.01.006"},{"key":"2026081405451402000_14.8.e015066.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.05.009"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2026-015066","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T12:45:24Z","timestamp":1786711524000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2026-015066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":42,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,14]]},"published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1136\/jitc-2026-015066"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2026-015066","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]}}}